Progression of classic Kaposi's sarcoma with rituximab.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 15965441.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rituximab is a monoclonal antibody directed against the CD20 antigen of B cells and is being used increasingly for treatment of antibody-mediated autoimmune diseases. We observed the rapid progression of Kaposi's sarcoma after our patient received rituximab for autoimmune hemolytic anemia. We postulate that by very specifically depleting B cells, rituximab affects T-cell function (eliminating B- and T-cell interactions), resulting in impaired T-cell-mediated immunity. Dermatologists should use caution when offering rituximab for off-label use.
Medical subject headings
- Antibodies, Monoclonal
- Immunologic Factors
- Sarcoma, Kaposi
- Skin Neoplasms